WNT5A and Obesity: In animal models of obesity and type 2 diabetes, Wnt5a triggers the activation of signaling pathways through JNK (c-jun N-terminal kinase) activation, and then contributes to low-grade inflammation, insulin resistance, and metabolic dysfunction in adipose tissue and atherosclerotic plaque16–19.